Pillars of long-term antiretroviral therapy success
Background: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and a continuous review of literature data on the efficacy and tolerability of new drugs a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_58e5cab26dd141baa29847630698de3b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Lucia Taramasso |e author |
| 700 | 1 | 0 | |a Massimo Andreoni |e author |
| 700 | 1 | 0 | |a Andrea Antinori |e author |
| 700 | 1 | 0 | |a Alessandra Bandera |e author |
| 700 | 1 | 0 | |a Paolo Bonfanti |e author |
| 700 | 1 | 0 | |a Stefano Bonora |e author |
| 700 | 1 | 0 | |a Marco Borderi |e author |
| 700 | 1 | 0 | |a Antonella Castagna |e author |
| 700 | 1 | 0 | |a Anna Maria Cattelan |e author |
| 700 | 1 | 0 | |a Benedetto Maurizio Celesia |e author |
| 700 | 1 | 0 | |a Stefania Cicalini |e author |
| 700 | 1 | 0 | |a Antonella Cingolani |e author |
| 700 | 1 | 0 | |a Andrea Cossarizza |e author |
| 700 | 1 | 0 | |a Antonella D'Arminio Monforte |e author |
| 700 | 1 | 0 | |a Gabriella D'Ettorre |e author |
| 700 | 1 | 0 | |a Antonio Di Biagio |e author |
| 700 | 1 | 0 | |a Simona Di Giambenedetto |e author |
| 700 | 1 | 0 | |a Giovanni Di Perri |e author |
| 700 | 1 | 0 | |a Vincenzo Esposito |e author |
| 700 | 1 | 0 | |a Emanuele Focà |e author |
| 700 | 1 | 0 | |a Cristina Gervasoni |e author |
| 700 | 1 | 0 | |a Andrea Gori |e author |
| 700 | 1 | 0 | |a Nicola Gianotti |e author |
| 700 | 1 | 0 | |a Giovanni Guaraldi |e author |
| 700 | 1 | 0 | |a Roberto Gulminetti |e author |
| 700 | 1 | 0 | |a Sergio Lo Caputo |e author |
| 700 | 1 | 0 | |a Giordano Madeddu |e author |
| 700 | 1 | 0 | |a Paolo Maggi |e author |
| 700 | 1 | 0 | |a Giorgio Marandola |e author |
| 700 | 1 | 0 | |a Giulia Carla Marchetti |e author |
| 700 | 1 | 0 | |a Claudio Maria Mastroianni |e author |
| 700 | 1 | 0 | |a Cristina Mussini |e author |
| 700 | 1 | 0 | |a Carlo Federico Perno |e author |
| 700 | 1 | 0 | |a Giuliano Rizzardini |e author |
| 700 | 1 | 0 | |a Stefano Rusconi |e author |
| 700 | 1 | 0 | |a Maria Santoro |e author |
| 700 | 1 | 0 | |a Loredana Sarmati |e author |
| 700 | 1 | 0 | |a Maurizio Zazzi |e author |
| 700 | 1 | 0 | |a Franco Maggiolo |e author |
| 245 | 0 | 0 | |a Pillars of long-term antiretroviral therapy success |
| 260 | |b Elsevier, |c 2023-10-01T00:00:00Z. | ||
| 500 | |a 1096-1186 | ||
| 500 | |a 10.1016/j.phrs.2023.106898 | ||
| 520 | |a Background: Meeting the challenge of antiretroviral therapy (ART) whose efficacy can last a lifetime requires continuous updating of the virological, pharmacological, and quality of life outcomes to be pursued and a continuous review of literature data on the efficacy and tolerability of new drugs and therapeutic strategies. Methods: With the aim of identifying open questions and answers about the current controversies in modern ART, we adapted the Design Thinking methodology to the needs of the design phase of a scientific article, involving a team of experts in HIV care. Results: Five main pillars of treatment success were discussed: sustained virologic suppression over time; immunological recovery; pharmacological attributes; long-term tolerability and safety of ART; and people's satisfaction and quality of life. The definition of the outcomes to be achieved in each thematic area and the tools to achieve them were reviewed and discussed. Conclusions: Long-term treatment success should be intended as a combination of HIV-RNA suppression, immune recovery, and high quality of life. To achieve this, the regimen should be well-tolerated, with high potency, genetic barrier, and forgiveness, and should be tailored by a person-centered perspective, based on individual needs, preferences, and therapeutic history. | ||
| 546 | |a EN | ||
| 690 | |a Antiretroviral therapy | ||
| 690 | |a Virologic suppression | ||
| 690 | |a Immunological recovery | ||
| 690 | |a Pharmacological attributes | ||
| 690 | |a Safety | ||
| 690 | |a Quality of life | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pharmacological Research, Vol 196, Iss , Pp 106898- (2023) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1043661823002542 | |
| 787 | 0 | |n https://doaj.org/toc/1096-1186 | |
| 856 | 4 | 1 | |u https://doaj.org/article/58e5cab26dd141baa29847630698de3b |z Connect to this object online. |